Pfizer Reports Positive Results for Abrocitinib as Dermatitis Treatment

Pfizer (PFE) on Saturday reported positive results from its phase 3, 12-week study of abrocitinib, an investigational oral treatment of patients aged 12 and older with moderate to severe atopic dermatitis.

The New York-based pharmaceutical company said that abrocitinib met all the co-primary and key secondary endpoints related to skin clearance and itch relief compared to placebo and that the drug if approved, may provide the first oral, once-daily treatment option for such patients.

In the study, 387 patients were selected to receive abrocitinib 200mg, abrocitinib 100mg, or placebo. In week 12, patients given doses of abrocitinib showed higher improvement on their Investigator Global Assessment score of clear or almost clear skin compared with those treated with placebo. In addition, more patients given doses of abrocitinib achieved 75% improvement on their Eczema Area and Severity Index score, compared with patients treated with placebo.

Pfizer presented the results of the study at the European Academy of Dermatology and Venereology Congress in Madrid.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*